The American Diabetes Association’s Standards of Care in Diabetes—2025-The American Diabetes Association’s Standards of Care in Diabetes

Video Transcription

Video Summary

In a recent webinar, updates on the American Diabetes Association's 2025 Standards of Care were discussed, focusing on their impact on type 2 diabetes, cardiovascular disease, and chronic kidney disease management. Dr. Alexander Chang and Dr. Dennis Brumer presented the session, emphasizing the need to adapt diabetes care to include recent advances in medical treatments aimed at improving cardiovascular and metabolic health outcomes.<br /><br />Key updates include new blood pressure targets, advances in lipid management, and the efficacy of newer therapeutic agents like GLP-1 receptor agonists and SGLT2 inhibitors. The importance of comprehensive risk management was highlighted, using data from significant trials such as the STINO2 trial, which underscores the importance of addressing multiple risk factors simultaneously.<br /><br />The speakers also discussed barriers to implementing these strategies in clinical practice, the role of HDL control in patients with diabetes, and the management of hyperlipidemia with a focus on the utilization of statins and non-statin therapies. Emphasis was placed on the benefits of SGLT2 inhibitors in reducing cardiovascular and kidney complications, even though their uptake remains low. Finally, questions from participants emphasized the practicalities of implementing these guidelines, including medication management and patient-specific adjustments.

Keywords

American Diabetes Association

2025 Standards of Care

type 2 diabetes

cardiovascular disease

chronic kidney disease

GLP-1 receptor agonists

SGLT2 inhibitors

lipid management

STINO2 trial